Comparative Pharmacology
Head-to-head clinical analysis: LARYNGOTRACHEAL ANESTHESIA KIT versus LIDOCAINE HYDROCHLORIDE 0 2 IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARYNGOTRACHEAL ANESTHESIA KIT versus LIDOCAINE HYDROCHLORIDE 0 2 IN DEXTROSE 5.
LARYNGOTRACHEAL ANESTHESIA KIT vs LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine and tetracaine are sodium channel blockers, inhibiting nerve impulse conduction, providing local anesthesia. Epinephrine is a vasoconstrictor that reduces systemic absorption and prolongs duration.
Lidocaine is a local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.
4 mL of 4% lidocaine (160 mg) via atomizer or nebulizer for topical laryngotracheal anesthesia, with additional 2 mL aliquots as needed, not to exceed 4.5 mg/kg total dose.
1-1.5 mg/kg IV bolus over 2-3 minutes, followed by continuous IV infusion of 1-4 mg/min for ventricular arrhythmias; maximum 3 mg/kg (or 200-300 mg) over 1 hour.
None Documented
None Documented
Lidocaine terminal half-life: 1.5–2 hours (normal hepatic function); prolonged to 3–5 hours in heart failure or hepatic disease. Tetracaine: 2–3 hours.
Terminal elimination half-life: 1.5-2 hours (adults); prolonged in heart failure (up to 4-6 hours) or hepatic impairment (up to 5-7 hours).
Renal excretion of lidocaine and its metabolites (primarily monoethylglycinexylidide (MEGX) and glycinexylidide (GX)); <10% unchanged. Biliary/fecal excretion minimal (<5%).
Renal: ~90% as metabolites and <10% unchanged. Biliary/fecal: minor (<1%).
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)